Federica Demma

Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy

Francesca Fiorentino, Beatrice Canali, Paolo Morelli, Federica Demma

Introduction: This study estimates the change in the costs of second-line or later (2L+) treatments compared to the current scenario, associated with the introduction of brentuximab vedotin (Adcetris®) (BV) in combination with doxorubicin, vinblastine and dacarbazine (A+AVD) for the treatment of previously …

it (code pays fourni par la source)

Savings associated with therapeutic appropriateness for patients with relapsed refractory multiple myeloma and high cytogenetic risk diagnosed by FISH test

Rossella Bitonti, Federica Demma, Massimiliano Rea, Gianluca Furneri

Background: Approximately 23% of myeloma patients have cytogenetic abnormalities which confer a significantly poorer prognosis, and therefore they are defined as “high-risk myeloma” (HRC+) patients. Objective: To estimate the economic impact of a large-scale use of the fluorescence in situ hybridization (FISH) …

it, de (code pays fourni par la source)

Cost analysis comparison of rurioctocog alfa pegol compared to turoctocog alfa pegol in the prophylaxis of Haemophilia A in Italy

Federica Demma, Pierpaola Arpa

Background: Hemophilia-A is an X-linked genetic disorder arising from a mutation to the X chromosome and causing either a quantitative or qualitative deficiency in blood clotting factor-VIII (FVIII). Several recombinant extended half-life FVIII products (rFVIII-EHL) are in use in Italy for the …

it (code pays fourni par la source)

POSB135 Budget Impact Analysis of Brigatinib for First-line Treatment of Alk-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Italy

Duccio Urbinati, P La Malfa, Federica Demma, Raffaella Viti et autres

us, it, gb (code pays fourni par la source)

Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy

Gian Luca Breschi, Federica Demma, Paolo Morelli, Maria De Francesco

Abstract Introduction: In Hodgkin Lymphoma (HL), the early administration of brentuximab vedotin (BV) represents a highly effective treatment to consolidate patients after autologous stem cell transplantation (ASCT). For this indication, the Summary of Product Characteristics (SPC) reports a lower medical resource utilization …

it (code pays fourni par la source)

PRO32 Extended Half-Life (EHL) Recombinant Factor VIII (RFVIII) for the Treatment of Hemophilia a in Italy: Cost of Treatment Comparison

Federica Demma, Guido Di Martino

it (code pays fourni par la source)

PCN189 An Estimate of NON-SMALL-Cell LUNG Cancer (NSCLC) Patients with ALK Translocation (ALK+) in Italy Eligible for Treatment with Tyrosine Kinase Inhibitors (TKI)

Federica Demma, Raffaella Viti

it (code pays fourni par la source)

PCN323 CHANGE IN TREATMENT PARADIGM OF ALK+ NON-SMALL CELL LUNG CANCER (NSCLC) IN THE ITALIAN REAL PRACTICE

Christopher T. Tucci, Maria Fico, Duccio Urbinati, Laura Fioravanti et autres

us, it (code pays fourni par la source)

PCN68 BRENTUXIMAB VEDOTIN FOR CONSOLIDATION THERAPY AFTER ASCT IN CD30+ HODGKIN'S LYMPHOMA: A SUSTAINABLE PHARMACEUTICAL EXPENDITURE FOR THE ITALIAN NATIONAL HEALTH SERVICE

Ilaria Peduto, Franca Heiman, Paolo Morelli, Laura Fioravanti et autres

us, it (code pays fourni par la source)

PCN216 - CONTEMPORARY REAL-WORLD EVIDENCES ON ALK+ NSCLC PATIENTS IN ITALY

Christopher T. Tucci, C. Persegani Trimarchi, Duccio Urbinati, Federica Demma et autres

it (code pays fourni par la source)

PCN200 - COST-OFFSETS ASSOCIATED WITH THE NEW TRIPLETS AVAILABLE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RESOURCE CONSUMPTION DERIVED FROM ITALIAN REAL PRACTICE

Claudio Ripellino, Ilaria Peduto, Franca Heiman, Laura Fioravanti et autres

it (code pays fourni par la source)

How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy

Lucia Taramasso, Federica Demma, Rossella Bitonti, Antonio Ferrazin et autres

BACKGROUND: The number of human immunodeficiency virus (HIV)-related hospitalizations has decreased worldwide in recent years, due to the availability of combined antiretroviral therapies (cART). The present analysis aimed to analyse the economic, and clinical burden of HIV management, after the introduction of …

it, us (code pays fourni par la source)